Pneumonia

Comparison of High Doses of Meropenem with its Usual Dose in increasing the effect of Cholestine on the treatment of ventilator-dependent pneumonitis resulting from Acintobacter

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210405050848N1

Enrollment

Registered

2021-06-07

Start date

2021-05-20

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia.

Interventions

Intervention 1: Intervention group: Continuous infusion of Meropenem(The intervention group will be given a 250 mg dose of Meropenem ampule as a continuous infusion with a pump, and routine infusion o

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Having at least two VAP criteria (increase in WBC above 11000 and decrease in WBC below 4000, fever above 38.5, culture of pulmonary secretions sensitive to cleistine, changes in CXRay)

Exclusion criteria

Exclusion criteria: History of allergy to Meropenem

Design outcomes

Primary

Measure	Time frame
VAP (Ventilation Associated Pneumonia)caused by Acinetobacter. Timepoint: Before and 3 day After intervention. Method of measurement: VAP(Ventilation Associated Pneumonia) criteria.	—

Secondary

Measure	Time frame
Control of ventilator associated pneumonia. Timepoint: Before and 3 days after intervention. Method of measurement: VAP (Ventilation Associated Pneumonia) criteria.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJafar Vakili

Shahid Beheshti University of Medical Sciences

jafar.vakili@sbmu.ac.ir+98 21 2243 9770

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026